United States · Series B startup

Who invested in Endovascular Engineering

One round we have observed, with the 6 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$42Mraised across 1 round since 2025, from 2 sources

Latest round
Series B, $42MFeb 2025
Led by
415 Capital
Investors
6 (1 led)
See who backed them

The rounds

  1. Feb 2025

Everyone who backed them

415 CapitalVC firm1round, led 1
S3 VenturesVC firm1round
Sante VenturesVC firm1round
Panakes PartnersVC firm1round
CordisCorporate VC1round
M&L HealthcareGrowth equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Endovascular Engineering

Who invested in Endovascular Engineering?

Endovascular Engineering's investors include 415 Capital, S3 Ventures, Sante Ventures, Panakes Partners and Cordis, and 1 more on record. 415 Capital led its latest round.

How much has Endovascular Engineering raised?

Endovascular Engineering has raised $42M across 1 round since 2025.

When did Endovascular Engineering last raise?

Endovascular Engineering's most recent round was a Series B of $42M in Feb 2025, led by 415 Capital.

What was Endovascular Engineering's biggest round?

Its most recent round, $42M in Feb 2025, is also its largest on record.

Who backed Endovascular Engineering first?

Endovascular Engineering's first round on record, in Feb 2025, was backed by 415 Capital, S3 Ventures and Sante Ventures and 3 others.

What stage is Endovascular Engineering at?

Endovascular Engineering's latest named round is a Series B, in Feb 2025.

Where is Endovascular Engineering based?

Endovascular Engineering is based in the United States.

Who led Endovascular Engineering's rounds?

415 Capital led the Series B in 2025.

Companies like Endovascular Engineering

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.